An international research team led by the Institute of Bioengineering and Nanotechnology (IBN) of the Agency for Science, Technology and Research (A*STAR) and IBM Research developed a synthetic molecule that can kill five deadly types of multidrug-resistant bacteria with limited, if any, side effects. Their new material could be developed into an antimicrobial drug to treat patients with antibioticresistant infections.
This finding was reported in the scientific journal Nature Communications.
Superbugs that are resistant to antibiotics are a serious health threat. According to the UK Review on Antimicrobial Resistance, superbugs kill around 700,000 people worldwide each year. By 2050, 10 million people could die each year if existing antibiotics continue to lose their effectiveness.
“There is an urgent global need for new antimicrobials that are effective against superbugs. The situation has become more acute because bacteria are starting to develop resistance to the last-line antibiotics, which are given only to patients infected with bacteria resistant to available antibiotics,” said Professor Jackie Y. Ying, Executive Director of IBN.
The research community is trying to develop alternatives to antibiotics using synthetic polymers. However, the antimicrobial polymers developed so far are either too toxic for clinical use, not biodegradable or can only target one type of bacteria.
To address this problem, Dr Yi Yan Yang from IBN brought together a multidisciplinary research team from the US, China and Singapore to develop a new class of antimicrobial polymers called guanidinium-functionalized polycarbonates with a unique killing mechanism that can target a broad range of multidrug-resistant bacteria. It is biodegradable and non-toxic to human cells.
The polymer kills bacteria in the following way. First, the polymer binds specifically to the bacterial cell. Then, the polymer is transported across the bacterial cell membrane into the cytoplasm, where it causes precipitation of the cell contents (proteins and genes), resulting in cell death.
The team tested the polymers on mice infected with five hard-to-treat multidrug-resistant bacteria: Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, methicillinresistant Staphylococcus aureu and Pseudomonas aeruginosa. These superbugs are commonly acquired by patients in the hospitals and can cause systemic infections that lead to septic shock and multiple organ failure. The results showed that the bacteria were effectively removed from the mice and no toxicity was observed.
The researchers then further tested the effectiveness of the polymers on mice with two types of systemic infections caused by superbugs: peritonitis (an infection of the stomach’s inner lining) and lung infections from Pseudomonas aeruginosa. The polymers eliminated the bacterial infections in both groups of mice with negligible toxicity.
Dr Yi Yan Yang, Group Leader at IBN said, “We have demonstrated the first example of a biodegradable synthetic macromolecule with broad-spectrum antimicrobial activity in mice, unique killing mechanism and no toxicity. Once the polymer finishes its job of killing the bacteria, it will be naturally degraded after three days and will not remain in the body. This antimicrobial agent shows great promise for the treatment and prevention of multidrug-resistant systemic infections.”
“This study illustrates the potential for this new research field we denote as ‘macromolecular therapeutics’ to create entirely new classes of treatments for multiple diseases,” said Dr James Hedrick, Distinguished Research Staff Member, IBM Research – Almaden, San Jose, California. “In 2016, we demonstrated the efficacy of synthetic polymers to combat deadly viral diseases. The current research for treating bacterial infections rounds out our ability to someday treat a spectrum of infectious diseases with a single, new type of mechanism without the onset of resistance.”
To determine whether the bacteria will develop any resistance to the polymer, the team collaborated with Dr Paola Florez de Sessions at A*STAR’s Genome Institute of Singapore and the Cell Engineering group of Dr Simone Bianco at IBM Research – Almaden to perform genomic analysis. They found that the bacteria did not show any resistance development even after multiple treatments with the polymer.
The Latest on: Antimicrobial drug
- FDA Proposes Subscription Model to Prod Antibiotic Development on September 17, 2018 at 5:20 pm
Gottlieb said sustaining "a strong antibiotic drug pipeline" is critical to fighting antibiotic resistance, but antibiotic development is not profitable for most pharmaceutical companies. "Large pharm... […]
- US FDA ups the ante against antimicrobial resistance on September 17, 2018 at 6:11 am
Second, we’re promoting antimicrobial stewardship ... which would see hospitals paying a “flat rate” to gain access to newly developed drugs. The fee that would be charged for the medicine, Gottlieb s... […]
- Stewardship is key to new FDA antimicrobial strategy on September 14, 2018 at 2:22 pm
Bringing all medically important antimicrobial drugs approved for use in animals under veterinary oversight and promoting proper stewardship of antimicrobials are among the goals of a five-year plan r... […]
- Gottlieb pitches ‘subscriptions’ to incentivize pharma to make new antibiotics on September 14, 2018 at 7:32 am
First, as bacteria become immune to the current arsenal of antibiotic medicines, more than 20,000 Americans are dying each year from these hard-to-treat infections. Drug companies, however, have few f... […]
- Drug exec blasted for claiming 'moral' right to hike antibiotic prices, supporting 'pharma bro' Shkreli on September 14, 2018 at 5:51 am
Move over, “Pharma Bro.” A new CEO is in the running as the pharmaceutical industry’s most despised executive after claiming he has the “moral” right to raise the price of a crucial antibiotic. Nirmal ... […]
- FDA to outline antibiotic strategy on September 14, 2018 at 4:09 am
The details: The plan also includes steps to promote careful antibiotic stewardship in human and animal ... use them sparingly enough that pathogens don't become resistant, but a drug companies’ profi... […]
- Scientists develop first non-antibiotic drug to treat TB on September 13, 2018 at 10:49 am
Scientists at the University of Manchester have developed the first non-antibiotic drug to successfully treat tuberculosis in animals. The team hope the compound -developed after 10 years of painstaki... […]
- A new antibiotic uses sneaky tactics to kill drug-resistant superbugs on September 12, 2018 at 10:21 am
Drug-resistant bacteria have a new challenger. A new molecule can kill deadly strains of common bacteria, such as Escherichia coli and Klebsiella pneumonia, that are resistant to most existing antibio... […]
- Mutant superbugs found in supermarket chicken and pork and antibiotics have NO effect on them on September 8, 2018 at 1:43 am
coli, campylobacter, and salmonella in hundreds of random samples of store-bought chicken and pork One sample of pork mince contained a strain of potentially-lethal bacteria that fought off the 'last- ... […]
- Drugs Team Up to Counter Antibiotic Resistance on September 5, 2018 at 2:34 pm
As the crisis of antibiotic resistance deepens, researchers are looking for new ways to combat infectious diseases. One solution proposed by UCLA researchers: When one drug won’t work, try two. […]
via Google News and Bing News